Efficacy of different doses of rt-PA in treatment of acute cerebral infarction
- VernacularTitle:探究不同剂量的rt-PA静脉溶栓治疗急性脑梗死的疗效
- Author:
Lei SHI
;
Kefei FU
- Publication Type:Journal Article
- Keywords:
acute cerebral infarction;
neurological defects;
recombinant tissue plasminogen activator
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;35(10):102-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore different doses of recombinant tissue-type plasminogen activator (rt-PA) intravenous thrombolytic therapy for acute cerebral infarction.Methods 130 patients with acute cerebral infarction were as the research subjects selected from May 2014 to May 2015 for rt-PA thrombolytic therapy, who were divided into two groups according to rt-PA thrombolytic agent dose, 65 cases in each group.Evaluated the clinical efficacy of thrombolytic therapy after treatment in accordance within 24 h intracerebral hemorrhage (ICH) , symptomatic intracerebral hemorrhage (SICH) , other bleeding symptoms and for 3 months after treatment the prognosis was good rate, total mortality.For pre-treatment, the degree of defect nerve function after two groups of patients were scored by NIHSS score, correlation analysis between the two groups of clinical efficacy and function of the degree of nerve defect before treatment.Results 3 months after thrombolysis total mortality in the standard dose group was significantly higher than that in the low-dose group (P<0.05) .After treatment, both groups NIHSS scores were significantly lower than before treatment (P<0.05); After treatment, NIHSS score 4-8 points in the proportion of low-dose group was significantly more than that in the standard dose group (P<0.05); NIHSS score 9-16 points, 17-24 points in the proportion of low-dose group were significantly less than that in the standard dose group (P<0.05).NIHSS9-16 points of patients after total mortality three months in the standard-dose group was significantly higher than that in the low-dose group (P<0.05) . Conclusion Different doses of rt-PA thrombolytic therapy in acute cerebral infarction are basically the same, and the degree of neurological deficit does not affect the efficacy, but reduce mortality in patients 3 months after low-dose rt-PA treatment, it is worth widely used in clinical practice.
